West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) VP Charles Witherspoon sold 703 shares of the firm's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $310.40, for a total value of $218,211.20. Following the completion of the transaction, the vice president now owns 1,253 shares in the company, valued at $388,931.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Charles Witherspoon also recently made the following trade(s):
- On Monday, August 19th, Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock. The stock was sold at an average price of $300.00, for a total value of $308,700.00.
West Pharmaceutical Services Trading Down 1.6 %
WST stock traded down $5.12 during midday trading on Thursday, hitting $307.90. 966,427 shares of the company's stock were exchanged, compared to its average volume of 569,893. The stock's fifty day moving average price is $301.40 and its 200-day moving average price is $320.19. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $413.70. The company has a market cap of $22.30 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 23.68 and a beta of 1.01. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.35. The firm had revenue of $746.90 million for the quarter, compared to the consensus estimate of $709.62 million. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The company's revenue for the quarter was down .1% on a year-over-year basis. During the same quarter last year, the business posted $2.16 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.55 earnings per share for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th will be given a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from West Pharmaceutical Services's previous quarterly dividend of $0.20. West Pharmaceutical Services's payout ratio is currently 12.46%.
Hedge Funds Weigh In On West Pharmaceutical Services
Institutional investors have recently bought and sold shares of the business. Sumitomo Mitsui Trust Holdings Inc. increased its position in West Pharmaceutical Services by 1.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier's stock worth $75,766,000 after buying an additional 2,759 shares during the last quarter. Mizuho Markets Americas LLC increased its position in West Pharmaceutical Services by 142.3% during the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier's stock worth $11,724,000 after buying an additional 17,399 shares during the last quarter. Tidal Investments LLC increased its position in West Pharmaceutical Services by 54.7% during the first quarter. Tidal Investments LLC now owns 10,574 shares of the medical instruments supplier's stock worth $4,181,000 after buying an additional 3,738 shares during the last quarter. SG Americas Securities LLC increased its position in West Pharmaceutical Services by 44.4% during the first quarter. SG Americas Securities LLC now owns 12,365 shares of the medical instruments supplier's stock worth $4,893,000 after buying an additional 3,802 shares during the last quarter. Finally, Bahl & Gaynor Inc. increased its position in West Pharmaceutical Services by 70.1% during the first quarter. Bahl & Gaynor Inc. now owns 4,976 shares of the medical instruments supplier's stock worth $1,969,000 after buying an additional 2,050 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
